Sir Gregory Winter | |
---|---|
Master of Trinity College, Cambridge | |
In office 2012–2019 | |
Preceded by | Baron Rees of Ludlow |
Succeeded by | Dame Sally Davies |
Personal details | |
Born | Gregory Paul Winter 14 April 1951 Leicester,Leicestershire,England |
Website | LMB web page |
Education | Royal Grammar School,Newcastle upon Tyne |
Alma mater | Trinity College,Cambridge (MA,PhD) |
Known for | Cambridge Antibody Technology Domantis [1] Bicycle Therapeutics [2] Antibody engineering |
Awards | Colworth Medal (1986) EMBO Member (1987) [3] Louis-Jeantet Prize for Medicine (1989) [4] Knight Bachelor (2004) Royal Medal (2011) Prince Mahidol Award (2016) [5] Nobel Prize in Chemistry (2018) Copley Medal (2024) |
Scientific career | |
Fields | Biochemistry |
Institutions | University of Cambridge Laboratory of Molecular Biology Imperial College London |
Thesis | The amino acid sequence of tryptophanyl tRNA synthetase from Bacillus stearothermophilus (1977) |
Doctoral advisor | Brian S. Hartley |
Sir Gregory Paul Winter CBE FRS FMedSci (born 14 April 1951) [6] [7] is a Nobel Prize-winning English molecular biologist best known for his work on the therapeutic use of monoclonal antibodies. His research career has been based almost entirely at the MRC Laboratory of Molecular Biology and the MRC Centre for Protein Engineering,in Cambridge,England.
He is credited with having invented techniques to both humanize (1986) and,later,to fully humanize using phage display,antibodies for therapeutic uses. [2] [8] [9] [10] [11] [12] [13] Previously,antibodies had been derived from mice,which made them difficult to use in human therapeutics because the human immune system had anti-mouse reactions to them. [6] [14] [15] [16] [17] [18] For these developments Winter was awarded the 2018 Nobel Prize in Chemistry along with George Smith and Frances Arnold. [19] [20]
He is a Fellow of Trinity College,Cambridge and was appointed Master of Trinity College,Cambridge on 2 October 2012,remaining in office until 2019. From 2006 to 2011,he was Deputy Director of the Laboratory of Molecular Biology,Medical Research Council,acting Director from 2007 to 2008 and Head of the Division of Protein and Nucleic Acids Chemistry from 1994 to 2006. He was also Deputy Director of the MRC Centre for Protein Engineering from 1990 to its closure in 2010. [21] [22]
Winter was educated at the Royal Grammar School,Newcastle upon Tyne. [6] He went on to study Natural Sciences at the University of Cambridge graduating from Trinity College,Cambridge in 1973. He was awarded a PhD degree,from the MRC Laboratory of Molecular Biology,for research on the amino acid sequence of tryptophanyl tRNA synthetase from the bacterium Bacillus stearothermophilus in 1977 [23] supervised by Brian S. Hartley. [24] Later,Winter completed a term of post-doctoral fellowship at Imperial College London,and another at the Institute of genetics in University of Cambridge. [25]
Following his PhD,Winter completed postdoctoral research at the Laboratory of Molecular Biology in Cambridge. [26] [27] He continued to specialise in protein and nucleic acid sequencing and became a Group Leader at the MRC Laboratory of Molecular Biology in 1981. He became interested in the idea that all antibodies have the same basic structure,with only small changes making them specific for one target. Georges J. F. Köhler and César Milstein had won the 1984 Nobel Prize for their work at the Laboratory of Molecular Biology,in discovering a method to isolate and reproduce individual,or monoclonal,antibodies from among the multitude of different antibody proteins that the immune system makes to seek and destroy foreign invaders attacking the body. [28] These monoclonal antibodies had limited application in human medicine,because mouse monoclonal antibodies are rapidly inactivated by the human immune response,which prevents them from providing long-term benefits.
Winter pioneered a technique to "humanise" mouse monoclonal antibodies;a technique used in the development of Campath-1H by the Laboratory of Molecular Biology and University of Cambridge scientists. [29] This antibody now looks promising for the treatment of multiple sclerosis. Humanized monoclonal antibodies form the majority of antibody-based drugs on the market today and include several blockbuster antibodies,such as Keytruda.
Winter founded Cambridge Antibody Technology in 1989, [30] [31] and Bicycle Therapeutics. [32] [33] He worked on the Scientific Advisory Board of Covagen, [34] [35] (now part of Cilag) and is also the chairman of the Scientific Advisory Board for Biosceptre International Limited.
In 1989,Winter was a founder of Cambridge Antibody Technology,one of the early commercial biotech companies involved in antibody engineering. One of the most successful antibody drugs developed was HUMIRA (adalimumab),which was discovered by Cambridge Antibody Technology as D2E7,and developed and marketed by Abbott Laboratories. HUMIRA,an antibody to TNF alpha,was the world's first fully human antibody, [36] which went on to become the world's top selling pharmaceutical with sales of over $18Bn in 2017 [37] Cambridge Antibody Technology was acquired by AstraZeneca in 2006 for £702m. [38]
In 2000,Winter founded Domantis to pioneer the use of domain antibodies,which use only the active portion of a full-sized antibody. Domantis was acquired by the pharmaceutical GlaxoSmithKline in December 2006 for £230 million. [1] [39]
Winter subsequently founded another company,Bicycle Therapeutics Limited as a start up company which is developing very small protein mimics based on a covalently bonded hydrophobic core. [40]
Winter was elected a Fellow of the Royal Society (FRS) in 1990 [41] and awarded the Royal Medal by the society in 2011 "for his pioneering work in protein engineering and therapeutic monoclonal antibodies,and his contributions as an inventor and entrepreneur". [42] He was given the Scheele Award in 1994.
In 1995,Winter won several international awards including the King Faisal International Prize for Medicine (Molecular Immunology) and in 1999,the Cancer Research Institute William B. Coley Award. Winter was formerly the Joint Head of the Division of Protein and Nucleic acid Chemistry-Biotechnology,and was Deputy Director, [43] at the Laboratory of Molecular Biology,Cambridge,an institution funded by the UK Medical Research Council. He was also Deputy Director of the MRC's Centre for Protein Engineering until its absorption into the Laboratory of Molecular Biology. He is a member of the Advisory Council for the Campaign for Science and Engineering. [44] Winter was appointed Commander of the Order of the British Empire (CBE) in 1997 and Knight Bachelor in 2004. He served as Master of Trinity College,Cambridge from 2012 to 2019. [45] [46] In 2015 he received the Wilhelm Exner Medal. [47]
Along with George Smith,Winter was awarded half of the Nobel Prize in Chemistry on 3 October 2018 for his work on phage displays for antibodies (while Frances Arnold received the other half of the prize that same year "for the directed evolution of enzymes"). [19] In 2020 he was featured on The Times' 'Science Power List'. [48] [49] In 2024 he received the Copley Medal of the Royal Society. [50]
Frederick Sanger was a British biochemist who received the Nobel Prize in Chemistry twice.
Michael Smith was a British-born Canadian biochemist and businessman. He shared the 1993 Nobel Prize in Chemistry with Kary Mullis for his work in developing site-directed mutagenesis. Following a PhD in 1956 from the University of Manchester,he undertook postdoctoral research with Har Gobind Khorana at the British Columbia Research Council in Vancouver,British Columbia,Canada. Subsequently,Smith worked at the Fisheries Research Board of Canada Laboratory in Vancouver before being appointed a professor of biochemistry in the UBC Faculty of Medicine in 1966. Smith's career included roles as the founding director of the UBC Biotechnology Laboratory and the founding scientific leader of the Protein Engineering Network of Centres of Excellence (PENCE). In 1996 he was named Peter Wall Distinguished Professor of Biotechnology. Subsequently,he became the founding director of the Genome Sequencing Centre at the BC Cancer Research Centre.
A monoclonal antibody is an antibody produced from a cell lineage made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell.
Sir John Cowdery Kendrew,was an English biochemist,crystallographer,and science administrator. Kendrew shared the 1962 Nobel Prize in Chemistry with Max Perutz,for their work at the Cavendish Laboratory to investigate the structure of haem-containing proteins.
The Medical Research Council (MRC) is responsible for co-coordinating and funding medical research in the United Kingdom. It is part of United Kingdom Research and Innovation (UKRI),which came into operation 1 April 2018,and brings together the UK's seven research councils,Innovate UK and Research England. UK Research and Innovation is answerable to,although politically independent from,the Department for Business,Energy and Industrial Strategy.
César Milstein,CH,FRS was an Argentine biochemist in the field of antibody research. Milstein shared the Nobel Prize in Physiology or Medicine in 1984 with Niels Kaj Jerne and Georges J. F. Köhler for developing the hybridoma technique for the production of monoclonal antibodies.
Phage display is a laboratory technique for the study of protein–protein,protein–peptide,and protein–DNA interactions that uses bacteriophages to connect proteins with the genetic information that encodes them. In this technique,a gene encoding a protein of interest is inserted into a phage coat protein gene,causing the phage to "display" the protein on its outside while containing the gene for the protein on its inside,resulting in a connection between genotype and phenotype. The proteins that the phages are displaying can then be screened against other proteins,peptides or DNA sequences,in order to detect interaction between the displayed protein and those of other molecules. In this way,large libraries of proteins can be screened and amplified in a process called in vitro selection,which is analogous to natural selection.
Georges Jean Franz Köhler was a German biologist.
Sir John Ernest Walker is a British chemist who won the Nobel Prize in Chemistry in 1997. As of 2015 Walker is Emeritus Director and Professor at the MRC Mitochondrial Biology Unit in Cambridge,and a Fellow of Sidney Sussex College,Cambridge.
The Medical Research Council (MRC) Laboratory of Molecular Biology (LMB) is a research institute in Cambridge,England,involved in the revolution in molecular biology which occurred in the 1950–60s. Since then it has remained a major medical research laboratory at the forefront of scientific discovery,dedicated to improving the understanding of key biological processes at atomic,molecular and cellular levels using multidisciplinary methods,with a focus on using this knowledge to address key issues in human health.
Richard Henderson is a British molecular biologist and biophysicist and pioneer in the field of electron microscopy of biological molecules. Henderson shared the Nobel Prize in Chemistry in 2017 with Jacques Dubochet and Joachim Frank. "Thanks to his work,we can look at individual atoms of living nature,thanks to cryo-electron microscopes we can see details without destroying samples,and for this he won the Nobel Prize in Chemistry."
Dame Jean Olwen Thomas,is a Welsh biochemist,former Master of St Catharine's College,Cambridge,and Chancellor of Swansea University.
The Sir William Dunn School of Pathology is a department within the University of Oxford. Its research programme includes the cellular and molecular biology of pathogens,the immune response,cancer and cardiovascular disease. It teaches undergraduate and graduate courses in the medical sciences.
Morten Peter Meldal is a Danish chemist and Nobel laureate. He is a professor of chemistry at the University of Copenhagen in Copenhagen,Denmark. He is best known for developing the CuAAC-click reaction,concurrently with but independent of Valery V. Fokin and K. Barry Sharpless.
Cambridge Antibody Technology Group Plc,was a biotechnology company headquartered in Cambridge,England,United Kingdom. Its core focus was on antibody therapeutics,primarily using Phage Display and Ribosome Display technology.
John McCafferty is a British scientist,one of the founders of Cambridge Antibody Technology alongside Sir Gregory Winter and David Chiswell. He is well known as one of the inventors of scFv antibody fragment phage display,a technology that revolutionised the monoclonal antibody drug discovery. McCafferty and his team developed this process following failures previously generating antibodies by immunizing mice. Later improvements of antibody phage display technology enables the display of millions of different antibody fragments on the surface of filamentous phage and subsequent selection of highly specific recombinant antibodies to any given target. This technology is widely exploited in pharmaceutical industry for the discovery and development of therapeutic monoclonal antibodies to treat mainly cancer,inflammatory and infectious diseases. One of the most successful was HUMIRA (adalimumab),discovered by Cambridge Antibody Technology as D2E7 and developed and marketed by Abbott Laboratories. HUMIRA,an antibody to TNF alpha,was the world's first phage display derived fully human antibody,which achieved annual sales exceeding $1bn therefore achieving blockbuster status. Humira went on to dominate the best-selling drugs lists - in 2016:The best selling drugs list researched by Genetic Engineering &Biotechnology News,published in March 2017,details that Humira occupied the number 1 position for 2015 and 2016. Whilst for 2017,Abbvie reports that Humira achieved $18.427billion of sales in 2017
Ff phages is a group of almost identical filamentous phage including phages f1,fd,M13 and ZJ/2,which infect bacteria bearing the F fertility factor. The virion is a flexible filament measuring about 6 by 900 nm,comprising a cylindrical protein tube protecting a single-stranded circular DNA molecule at its core. The phage codes for only 11 gene products,and is one of the simplest viruses known. It has been widely used to study fundamental aspects of molecular biology. George Smith and Greg Winter used f1 and fd for their work on phage display for which they were awarded a share of the 2018 Nobel Prize in Chemistry. Early experiments on Ff phages used M13 to identify gene functions,and M13 was also developed as a cloning vehicle,so the name M13 is sometimes used as an informal synonym for the whole group of Ff phages.
Terence Howard Rabbitts FRS FMedSci is currently Professor of Molecular Immunology at the Institute of Cancer Research,London.
Jane Osbourn,OBE,is a scientist and former chair of the UK BioIndustry Association.
Philipp Holliger is a Swiss molecular biologist best known for his work on xeno nucleic acids (XNAs) and RNA engineering. Holliger is a program leader at the MRC Laboratory of Molecular Biology.
This article incorporates text available under the CC BY 4.0 license.